Trial Profile
A phase III study comparing T-DM1 with pertuzumab, trastuzumab and docetaxel in elderly patients with advanced stage HER2 positive breast cancer (JCOG1607, HERB TEA study)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Docetaxel
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms HERB TEA study
- 12 Feb 2024 Planned number of patients changed from 330 to 250.
- 04 Jun 2019 According to an abstract presented at the 55th Annual Meeting of the American Society of Clinical Oncology, nineteen patients have been enrolled as of January 2019.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology